0001104659-26-055014
SEC filingModest revenue growth of 2.0% to $453.2M was overshadowed by a 51.8% drop in net income to $40.2M, driven by restructuring charges, higher R&D, and Healthcare patient monitoring declines, though operating cash flow surged to $97.0M from working capital normalization.
Revenue rose 2.0% to $453.2 million in Q3 fiscal 2026 from $444.4 million a year ago, reflecting resilience amid mixed divisional performance. Gross profit remained flat at $150.3 million, maintaining a 33.2% margin as revenue growth balanced any product mix pressures. This stability underscores the company's ability to manage costs effectively even as Healthcare faced headwinds.
Operating income decreased 5.3% to $53.2 million from $56.2 million, pressured by elevated R&D expenses. These costs rose due to increased compensation for new product development initiatives across Security and Healthcare divisions. The 11.7% operating margin reflects disciplined expense management amid these investments, positioning the company for future growth in key areas like aviation screening systems and radio frequency products, which drove product revenue increases.
Cash generation provided a bright spot, with net cash from operating activities flipping to $97.0 million from a -$58.5 million outflow last year. This surge, despite unfavorable working capital changes like lower customer advances and deferred revenue impacts, generated $79.3 million in free cash flow after $17.7 million in capital expenditures. Cash flows inherently fluctuate with net income, non-cash adjustments, and working capital dynamics, but strong underlying operations bolster liquidity alongside cash equivalents and credit facilities.
Looking ahead, ongoing global conflicts and instability introduce uncertainty in security, political, budget, and regulatory environments. Management will monitor these factors' effects on business and results, emphasizing R&D to fuel Security and Healthcare innovation while navigating Healthcare recovery and restructuring returns.